Novavax (NVAX) says phase 1 data for COVID-19 vaccine candidate show it was generally well-tolerated and elicited robust antibody responses

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. FDX
4. META
5. ABBV
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Novavax (NVAX) says phase 1 data for COVID-19 vaccine candidate show it was generally well-tolerated and elicited robust antibody responses

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate

August 4, 2020 4:04 PM EDT

Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax COVID-19 vaccine across two dose levels (5 and 25 µg) in 131 healthy adults ages 18-59 yearsNVX-CoV2373 was generally well-tolerated and had a reassuring safety profileThe vaccine induced neutralization titers in 100% of participants Both 5 µg and 25 µg adjuvanted doses generated peak geometric mean titer (GMT) greater than 1:3,300 Matrix-M adjuvant induced robust polyfunctional CD4+ T cell responsesConference call to be held on Tuesday, August 4 at... More